title: Lapatinib induces p27(Kip1)-dependent G₁ arrest through both transcriptional and post-translational mechanisms.
abstract: Lapatinib, a dual EGFR/HER2 tyrosine kinase inhibitor, has been shown to have potent antitumor effects against human breast cancer. Recent studies have shown that lapatinib upregulates p27(Kip1) (here after referred to as p27) expression and induces G₁ cell cycle arrest in various types of cancer cells. However, the regulation of p27 in lapatinib-induced cell cycle arrest is not well studied. Here we demonstrate that lapatinib-induced cell growth inhibition and G₁ cell cycle arrest in HER2-overexpressing human breast cancer cells were dependent on p27. We also show that lapatinib-induced upregulation of p27 expression was mediated through both transcriptional and post-translational mechanisms. On the one hand, lapatinib treatment led to increased FOXO3a expression and enhanced p27 transcription. On the other hand, lapatinib treatment resulted in increased DYRK1B expression, which correlated with increased p27 phosphorylation at Ser10 and decreased p27 degradation. Interestingly, we found that ERβ1 but not ERβ2 expression also upregulated p27 and enhanced lapatinib-induced cell proliferation inhibition and G₁ cell cycle arrest in HER2-overexpressing breast cancer cells. Taken together, our results suggest that lapatinib induces p27 expression via both transcriptional and post-translational upregulations, leading to cell cycle arrest and cell proliferation inhibition, and that its effect on breast cancer cells may be modified by ER expression status.
authors.affiliation: Department of Medical Oncology, Jinling Hospital; Nanjing University School of Medicine, Nanjing, PR China.
authors.forename: Lin
authors.initials: L
authors.lastname: Tang
authors.forename: Yucai
authors.initials: Y
authors.lastname: Wang
authors.forename: Anders
authors.initials: A
authors.lastname: Strom
authors.forename: Jan-Åke
authors.initials: JÅ
authors.lastname: Gustafsson
authors.forename: Xiaoxiang
authors.initials: X
authors.lastname: Guan
mesh_terms: D015153:Blotting, Western; D045744:Cell Line, Tumor; D050760:Cyclin-Dependent Kinase Inhibitor p27 / Q000378:metabolism*; D017931:DNA Primers / Q000235:genetics; D066246:ErbB Receptors / Q000037:antagonists & inhibitors; D005434:Flow Cytometry; D000071316:Forkhead Box Protein O3; D051858:Forkhead Transcription Factors / Q000378:metabolism; D059585:G1 Phase Cell Cycle Checkpoints / Q000187:drug effects*; D005786:Gene Expression Regulation / Q000187:drug effects*; D006801:Humans; D000077341:Lapatinib; D008954:Models, Biological; D010766:Phosphorylation; D017346:Protein Serine-Threonine Kinases / Q000378:metabolism; D011505:Protein-Tyrosine Kinases / Q000378:metabolism; D011799:Quinazolines / Q000494:pharmacology*; D034622:RNA Interference; D060888:Real-Time Polymerase Chain Reaction; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000037:antagonists & inhibitors; D000097603:Dyrk Kinases
chemical_list: D050760:Cyclin-Dependent Kinase Inhibitor p27; D017931:DNA Primers; D066246:ErbB Receptors; D000071316:Forkhead Box Protein O3; D051858:Forkhead Transcription Factors; D000077341:Lapatinib; D017346:Protein Serine-Threonine Kinases; D011505:Protein-Tyrosine Kinases; D011799:Quinazolines; D018719:Erb-b2 Receptor Tyrosine Kinases; D000097603:Dyrk Kinases; C499517:FOXO3 protein, human; C512478:EGFR protein, human; C508053:ERBB2 protein, human
keywords: ERÎ²1; ERÎ²2; G1 arrest; lapatinib; p27
references.citation: Oncotarget. 2012 Dec;3(12):1600-14
references.pmid: 23307622
references.citation: FEBS Lett. 2001 Feb 16;490(3):179-89
references.pmid: 11223033
references.citation: J Biol Chem. 2004 May 21;279(21):22498-504
references.pmid: 15010468
references.citation: Genes Dev. 1997 Jun 1;11(11):1464-78
references.pmid: 9192873
references.citation: Cancer Prev Res (Phila). 2011 Aug;4(8):1190-7
references.pmid: 21791570
references.citation: Cancer Cell. 2010 Apr 13;17(4):319-32
references.pmid: 20385358
references.citation: Breast Cancer Res Treat. 2010 Sep;123(2):387-96
references.pmid: 19946741
references.citation: Mol Cancer Ther. 2007 May;6(5):1629-40
references.pmid: 17513611
references.citation: Cell Cycle. 2012 Apr 15;11(8):1583-92
references.pmid: 22441823
references.citation: Nat Rev Cancer. 2008 Apr;8(4):253-67
references.pmid: 18354415
references.citation: BMC Cancer. 2010 May 11;10:188
references.pmid: 20459769
references.citation: Breast Cancer Res Treat. 2011 Apr;126(2):395-405
references.pmid: 20490651
references.citation: Endocrinology. 2001 Sep;142(9):4120-30
references.pmid: 11517191
references.citation: Curr Top Microbiol Immunol. 1998;227:25-41
references.pmid: 9479824
references.citation: Breast Cancer Res. 2012 Nov 16;14(6):R148
references.pmid: 23158001
references.citation: Cell Cycle. 2012 Oct 1;11(19):3701-2
references.pmid: 22895010
references.citation: J Biol Chem. 1999 Nov 5;274(45):32309-17
references.pmid: 10542271
references.citation: EMBO J. 2001 Dec 3;20(23):6672-82
references.pmid: 11726503
references.citation: Cell Cycle. 2012 Apr 1;11(7):1468-76
references.pmid: 22441703
references.citation: Proc Natl Acad Sci U S A. 2004 Feb 10;101(6):1566-71
references.pmid: 14745018
references.citation: J Mol Endocrinol. 2005 Apr;34(2):553-66
references.pmid: 15821116
references.citation: Proc Natl Acad Sci U S A. 2000 Aug 1;97(16):9042-6
references.pmid: 10908655
references.citation: J Biol Chem. 2005 Feb 11;280(6):4894-905
references.pmid: 15546868
references.citation: Nucleic Acids Res. 1998 Aug 1;26(15):3505-12
references.pmid: 9671811
references.citation: Cancer Res. 2004 Jan 1;64(1):423-8
references.pmid: 14729654
references.citation: Genes Dev. 1999 Jun 15;13(12):1501-12
references.pmid: 10385618
references.citation: Cancer Res. 2011 Mar 15;71(6):2118-28
references.pmid: 21282336
references.citation: J Cell Physiol. 2000 Apr;183(1):10-7
references.pmid: 10699961
references.citation: Cancer Res. 2005 Jan 1;65(1):18-25
references.pmid: 15665275
references.citation: CA Cancer J Clin. 2011 Mar-Apr;61(2):69-90
references.pmid: 21296855
references.citation: Science. 1989 May 12;244(4905):707-12
references.pmid: 2470152
references.citation: Arch Histol Cytol. 2004 Dec;67(5):435-42
references.pmid: 15781984
references.citation: Cell Cycle. 2005 Jan;4(1):87-95
references.pmid: 15611642
references.citation: Proc Natl Acad Sci U S A. 2006 Nov 28;103(48):18350-5
references.pmid: 17110437
references.citation: Mol Cancer Res. 2005 Mar;3(3):163-9
references.pmid: 15798096
references.citation: Clin Cancer Res. 2012 Nov 1;18(21):5911-23
references.pmid: 22896656
references.citation: Curr Opin Cell Biol. 1993 Apr;5(2):187-93
references.pmid: 8507490
references.citation: Breast Cancer Res. 2005;7(4):R436-43
references.pmid: 15987448
references.citation: Oncogene. 2002 Sep 12;21(41):6255-63
references.pmid: 12214266
references.citation: J Biol Chem. 2005 Apr 1;280(13):12339-43
references.pmid: 15713665
references.citation: J Biol Chem. 2002 Apr 26;277(17):14355-8
references.pmid: 11889117
references.citation: Oncogene. 2001 Mar 29;20(14):1688-702
references.pmid: 11313917
references.citation: Int J Mol Med. 2011 Dec;28(6):985-91
references.pmid: 21887460
references.citation: Mol Endocrinol. 2012 Dec;26(12):1991-2003
references.pmid: 23028063
references.citation: Mol Cell Biol. 2000 Dec;20(24):9138-48
references.pmid: 11094066
references.citation: N Engl J Med. 2005 Oct 20;353(16):1659-72
references.pmid: 16236737
references.citation: Cancer Lett. 2008 Dec 18;272(2):296-306
references.pmid: 18774637
references.citation: Clin Cancer Res. 2008 Aug 15;14(16):5228-35
references.pmid: 18698041
references.citation: Oncotarget. 2011 Sep;2(9):728-36
references.pmid: 21908901
references.citation: J Clin Oncol. 2008 Jun 20;26(18):2999-3005
references.pmid: 18458039
references.citation: EMBO J. 1997 Sep 1;16(17):5334-44
references.pmid: 9311993
references.citation: Steroids. 2008 Oct;73(11):1039-51
references.pmid: 18501937
references.citation: Curr Biol. 1999 Jun 17;9(12):661-4
references.pmid: 10375532
references.citation: J Cell Mol Med. 2010 Apr;14(4):944-53
references.pmid: 19298520